Skip to main content
NewslettersWatchlist

Intellia Thera CS(NTLA-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low13.64
Day High14.58
Open:14.00
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock?
GlobeNewswire
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis
MarketBeat
3 Fast-Growing Stocks Analysts See Doubling in Price
GlobeNewswire
Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress
Motley Fool
Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day?
GlobeNewswire
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Motley Fool
This Beaten-Down Stock Could Soar by 354%, According to Wall Street
GlobeNewswire
Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024
Motley Fool
12 High-Growth Stocks That Could Deliver Parabolic Returns
Motley Fool
Why Intellia Therapeutics Stock Plummeted by 20% Today
GlobeNewswire
Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
Motley Fool
This Beaten-Down Growth Stock Could Skyrocket 234%, According to Wall Street
GlobeNewswire
Intellia Therapeutics Announces New Date for Upcoming Investor Webcast
Motley Fool
2 Cathie Wood Stocks That Could Soar 32% and 282%, According to Wall Street
GlobeNewswire
Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
GlobeNewswire
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Motley Fool
2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk
Barchart
This Cathie Wood Stock Can Soar 221%, Says Wall Street
Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Motley Fool
The Bull Case for Intellia Therapeutics Stock Just Got Even Stronger
Motley Fool
3 Stocks Cathie Wood Just Bought to Get Back on Track in the Second Half of 2024
Stock Target Advisor
3 Stocks to Watch on 6/28/2024: Investor Alert

Profile

Intellia Therapeutics is a leading clinical-stage genome editing company focused on developing CRISPR/Cas9-based therapeutics. The company is pursuing two primary approaches to fully realize the transformative potential of CRISPR/Cas9 in vivo programs that use intravenously administered CRISPR as the therapy and ex vivo programs that use CRISPR to create the therapy by using engineered human cells.'

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.